CSF3 and non-Hodgkin lymphoma: The first observation to be made is that the overall incidence of FN with the regimens investigated was higher than that which would be expected from the literature, particularly in cycles not protected by G-CSF prophylaxis (31% of breast cancer patients and 48% of NHL patients had FN in unprotected cycles).